Matthew Maxwell Donley - Mar 2, 2022 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Ex VP, Intern'l Operations
Signature
/s/ Matthew Maxwell Donley
Stock symbol
AUPH
Transactions as of
Mar 2, 2022
Transactions value $
-$36,655
Form type
4
Date filed
3/4/2022, 03:12 PM
Previous filing
May 12, 2021
Next filing
Nov 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Award $0 +8.5K +78.88% $0.00 19.3K Mar 2, 2022 Direct F1, F2
transaction AUPH Common Stock Sale -$36.7K -3.05K -15.83% $12.01 16.2K Mar 2, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Restricted Stock Unit Award $0 +104K $0.00 104K Mar 2, 2022 Common Shares 104K Direct F4
transaction AUPH Stock Option (right to buy) Award $0 +178K $0.00 178K Mar 2, 2022 Common Stock 178K $12.01 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
F2 Includes 876 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021.
F3 Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
F4 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
F5 One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.